Filipiinid - inglise - FDA (Food And Drug Administration)

n/a; importer: pnf pharmaceutical, inc; distributor: jackpharma inc - insulin human (rdna) - suspension for injection (im/sc) (100% isophane insulin human) - 100 iu/ml

Filipiinid - inglise - FDA (Food And Drug Administration)

n/a; importer: pnf pharmaceutical, inc; distributor: mega lifesciences limited inc - insulin human (rdna) - suspension for injection (im/sc) (100% isophane insulin human) - 100 iu/ml

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin r u-100 is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. humulin r u-100 may be administered intravenously under proper medical supervision in a clinical setting for glycemic control (see dosage and administration and storage). humulin r u-100 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to humulin r u-100 or any of its excipients. never share needles and syringes. correct syringe type doses of insulin are measured in units . u-100 insulin contains 100 units/ml (1 ml=1 cc). with humulin r, it is important to use a syringe that is marked for u-100 insulin preparations. failure to use the proper syringe can lead to a mistake in dosage, causing serious problems for you, such as a blood glucose level that is too low or too high. syringe use to help avoid contamination and possible infection, follow these instructions exactly. disposable syringes and needles should be used only

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate-acting; insulin (human)

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection in cartridge - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate-acting; insulin (human)

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

eli lilly nederland b.v. - human insulin (recombinant dna origin) - suspension for injection - 100 international unit(s)/millilitre - insulins and analogues for injection, intermediate-acting; insulin (human)

Malta - inglise - Malta Medicines Authority

eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

pfizer inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - kit - 1 mg - exubera is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. exubera has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. in patients with type 1 diabetes, exubera should be used in regimens that include a longer-acting insulin. in patients with type 2 diabetes, exubera can be used as monotherapy or in combination with oral agents or longer-acting insulins. exubera is contraindicated in patients hypersensitive to exubera or one of its excipients. exubera is contraindicated in patients who smoke or who have discontinued smoking less than 6 months prior to starting exubera therapy. if a patient starts or resumes smoking, exubera must be discontinued immediately due to the increased risk of hypoglycemia, and an alternative treatment must be utilized (see clinical pharmacology, special populations, smoking). the safety and efficacy of exube

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

tya pharmaceuticals - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - important: . do not change the type of insulin you use unless told to do so by your healthcare provider. the amount of insulin you take as well as the best time for you to take your insulin may need to change if you take a different type of insulin. know your insulin make sure that you know the type and strength of insulin that is prescribed for you. read the patient information leaflet that comes with novolin n before you start taking it and each time you get a refill. there may be new information. this leaflet does not take the place of talking with your healthcare provider about your diabetes or your treatment. make sure you know how to manage your diabetes. ask your healthcare provider if you have any questions about managing your diabetes. ® what is novolin n? ® novolin n is a man-made insulin (recombinant dna origin) nph, human insulin isophane suspension that is structurally identical to the insulin produced by the

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

eli lilly and company - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.5)] . risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7% and has been reported to be as high as 20-25% in women with a hba1c >10%. the estimated background risk of miscarriage for the indicated population is unkn